Expanding Treatment Horizons: Clinical Trial Data Updates for Myeloma

Published on

Topics include: Treatment

Renowned expert Dr. Gareth Morgan, from The UAMS Myeloma Institute, joined Patient Power at the 2018 American Society of Hematology (ASH) annual meeting to share emerging clinical trial research for the treatment of multiple myeloma. Dr. Morgan discusses the combinability of certain myeloma therapies, maintenance data and which patient subsets targeted treatments are suitable for. Dr. Morgan also touches on the expanded use of venetoclax and what it means for myeloma patients. Watch now to hear the latest news.

View more programs featuring , , and

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:

Gareth, so of the – a lot of news coming out of ASH. What’s really impressed you that’s significant for patients then in all this context?

Dr. Morgan:                

So, I think the combinability of Daratumumab with other agents so it doesn’t impair people’s quality of life, that seems to combine with everything well. And like predictably, theMAIAdata showed a great outcome up front. So, there’s a chance in the next year we’ll get it licensed for the upfront setting. The maintenance data with ixazomib (Ninlaro) looks good. And the data on the venetoclax (Venclexta) in myeloma is very encouraging. So, it’s a new mechanism of action that targets and programs cell death. So, it’s been a first in class drug like that for myeloma. It’s well tolerated and it works particularly well in the 11 to 14 subset of myeloma. 

Andrew Schorr:          

Jack, what about you? The news?

Jack Aiello:                 

I think those are all of them. And certainly, the CAR-T. But I’m still waiting to attend some oral sessions which occur tomorrow to hear more about the CAR=T therapies. 

But I think you’re spot on in terms of what’s been impressive so far. The venetoclax, as you said, works well in this T-11, 14 translocation. But the cool thing today was we saw it worked well for patients that don’t have that particular translocation. So – but it’s still early for some of these as well. 

Dr. Morgan:

So, to that helped Jack around the mechanism of location. Probably, he’d be saying that. So, it’s about how the myeloma cell survives. So, if it’s dependent on something called bcl-2, it’s cool. But often, it depends on something called ncl-1. And the proteasome inhibitor knocks down the ncl-1, sensitizes the cell to the venetoclax. So, the combination of those two agents is really enhancing the activity of the venetoclax. 

Esther Schorr:             

Can Venetoclax be added to elotuzumab (Empliciti) and lenalidomide (Revlimid)?

Dr. Morgan:                

So, we don’t really know the answer to that. But seeing as both of those drugs induce some type of cell death and kind of venetoclax makes you sensitive to cell death, maybe you could. But we’re always trying to be safe and effective. So, we wouldn’t necessarily put combinations together without having thought them through. And currently, those are not recommended combinations. 

Andrew Schorr:          

Right. And we should mention that venetoclax—which is approved in use in CLL and also now AML—is not yet approved in myeloma. You’ve talked about it before. So, some of this is figuring out in the FDA as well and looking for data. What can work either alone or in combination? Right? We’re not there. But it’s accelerating, so that’s good news. 

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

Myeloma News From ASH 2018: Encouraging Clinical Trial Updates From Dr. Ajai Chari

Patient Power founder Andrew Schorr is joined by leading myeloma expert Dr. Ajai Chari at the 2018 American Society of Hematology (ASH) annual meeting to discuss where there is an unmet need in myeloma care and share exciting clinical trial data with novel agents.

Published:

What Are the Challenges Myeloma Patients Face During a Clinical Trial?

What financial, emotional and physical difficulties do patients face during the clinical trial process? Watch as a panel of myeloma patients tell their stories.

Published:

What's a Myeloma Clinical Trial Like? Patients Share Their Experiences

What is clinical trial participation really like for patients? Watch this Myeloma Patient Café to hear the individual treatment journeys of four myeloma patients.

Published:

Myeloma Patient Perspective: Making the Decision to Join a Clinical Trial

Although a clinical trial may be recommended, patients make the final decision. Tune in as a myeloma patient panel discusses considerations before joining clinical trials and reasons to participate.

Published:

Does the Clinical Trial Process Need an Extreme Makeover?

In this MythBusters program, patient advocate Jim Omel and Dr. Michael Thompson examine barriers patients may face and discuss the safety and quality of clinical trial care. Does the process need a makeover? Watch now to find out more.

Published:

Will I Feel Like a Guinea Pig? A Four-Time Clinical Trial Participant Shares Her Experience

A common question patients have when considering a clinical trial is “will I be a guinea pig?” Meet Reina Weiner, a four-time clinical trial participant, as she shares her experience navigating the trial process, patient consent, safety, risks, family issues and more.

Published:

The Clinical Trial Process: An Explanation of How Efficacy and Patient Safety Are Monitored

A panel of experts explain the layers of review, or clinical trial phases, that go into the development of new therapies. How are MPN patients protected throughout the process? Watch now to also learn about safeguards in place before and during the study.

Published:

Patient-to-Patient Advice: Finding Support During the Clinical Trial Process

For people considering next steps on their treatment journey, it may be beneficial to hear from others who have ventured down a similar path. Watch now to hear a panel of multiple myeloma patients share tips for participating in a clinical trial and what they have found to be helpful.

Published:

How Can Clinical Trials Be Improved to Enhance the Patient Experience?

Patient advocate Jim Omel and leading expert Dr. Mike Thompson break down the design and purpose of clinical trials and give their perspective on how it could be more patient-friendly.

Published:

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on January 22, 2019